期刊文献+

紫杉醇靶向化疗在小细胞肺癌治疗中的疗效及药物相关不良反应分析 被引量:8

Analysis of the efficacy and drug-related adverse reactions of targeted chemotherapy with paclitaxel in the treatment of small cell lung cancer
下载PDF
导出
摘要 目的探究紫杉醇靶向化疗治疗小细胞肺癌的疗效及药物相关不良反应。方法根据治疗方法不同将82例小细胞肺癌患者分为对照组和观察组,各41例。对照组患者接受紫杉醇脂质体化疗,观察组患者接受紫杉醇靶向化疗。比较两组患者的疗效、药物相关不良反应发生情况、生活质量及治疗前后血清肿瘤标志物水平。结果治疗4个疗程后,观察组患者的治疗有效率高于对照组,药物相关不良反应轻于对照组,生活质量评分良好率高于对照组,差异均有统计学意义(P﹤0.05)。治疗2、4个疗程后,两组患者血清中癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、神经元特异性烯醇化酶(NSE)的表达水平均较本组治疗前降低,且观察组患者血清中CEA、CA125、CYFRA21-1、NSE的表达水平均低于同时间点对照组(P﹤0.05)。结论紫杉醇靶向化疗治疗小细胞肺癌的疗效较好,药物相关不良反应较轻,且可以有效降低血清肿瘤标志物水平,提高患者的生活质量。 Objective To investigate the clinical effect and drug-related adverse reactions of targeted chemotherapy with paclitaxel in the treatment of small cell lung cancer(SCLC).Method A total of 82 patients were included in the research and divided in to control group or study group according to the different treatments administered,with 41 patients in each.Patients in control group were treated with liposomal paclitaxel,while those in study group were given targeted chemotherapy with paclitaxel.The efficacy,drug-related adverse reactions,quality of life,as well as the pre-and posttreatment serum tumor markers of the two groups were compared.Result After 4 cycles of treatment,the response rate in study group was higher than that in control group,with lower severity of drug-related adverse reactions and better evaluations of quality of life score observed in study group compared to control group,with statistically significant differences noted(P<0.05).After 2 and 4 cycles of treatment,the expression of serum carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),and neuron specific enolase(NSE)were significantly reduced,and the serum CEA,CA125,CYFRA21-1,and NSE were lower than that of control group at the same time(P<0.05).Conclusion Targeted chemotherapy with paclitaxel demonstrates significant efficacy in the treatment of small cell lung cancer,with minor drug-related adverse reactions,and may reduce the level of serum tumor markers,thus improving the quality of life of patients.
作者 王冬冬 陈苏蓉 李成光 沈阳 陈亚平 WANG Dongdong;CHEN Surong;LI Chengguang;SHEN Yang;CHEN Yaping(Department of Oncology,Yancheng First Hospital,Yancheng 224000,Jiangsu,China)
出处 《癌症进展》 2019年第24期2945-2947,2997,共4页 Oncology Progress
关键词 紫杉醇 靶向化疗 小细胞肺癌 效果评价 药物相关不良反应 paclitaxel targeted chemotherapy small cell lung cancer effect evaluation drug-related adverse reaction
  • 相关文献

参考文献12

二级参考文献76

  • 1刘卓,徐丽贤,潘攀.奈达铂联合依托泊苷治疗小细胞肺癌的疗效观察[J].实用癌症杂志,2014,29(3):336-338. 被引量:5
  • 2王佳蕾,洪小南,印季良,杜敏琼,周彩存,熊建萍,徐农,陈颖波,许立功,侯惠民.紫杉醇脂质体与紫杉醇治疗非小细胞肺癌64例和乳腺癌62例的疗效[J].中国新药与临床杂志,2006,25(1):1-4. 被引量:19
  • 3Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in norr-small cell lung cancer: a meta-analysis using updated individual patient data from 52 randomised clinical trials[J]. Br Med J, 1995, 311(7):899-909.
  • 4Scagliotti GV, Fossati R, Torri V, et al. Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ, Ⅱ or Ⅲ A non-small-cell Lung cancer[J]. J Natl Cancer Inst, 2003,95 (19) : 1453-1461.
  • 5Kato H,Iehinose Y,Ohta M,et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung[J].N Engl J Med,2004,350(17):1713-1721.
  • 6Strauss G, Hemdon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin folowing resection in stage I B non-small cell lung cancer (NSCLC):Report of Cancer and Leukemia Group B(CALGB) Protocol 9633[J]. J Clin Oncol,2004,22(Suppl 14):612.
  • 7Horwitz SB. Mechanism of action of taxol[J]. Trends Pharmacol Sci, 1992,13(4) : 134-136.
  • 8Ganti A K, West W W, Lackner R P, et al. Current concepts in the diagnosis and management of small-cell lung cancer[J].Oncology, 2010, 24 ( 11 ) : 1034-1039.
  • 9Gerasimou G, Moralidis E, Gotzamani-Psarrakou A. Somatostatin receptor imaging with ( 111 ) Inpentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment[J]. Hell J Nucl Med, 2010, 13(2) :158-162.
  • 10Edelman M J, Clamon G, Kalm D, et al. Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 p2045, a somatostatin analog[J].J Thorac Oncol, 2009, 4(12) :1550-1554.

共引文献182

同被引文献91

引证文献8

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部